Why the study?
Although pharmacological therapy for HFrEF is scripted by guidelines, many eligible patients are not treated with guideline-directed medical therapy in clinical practice.
Does a navigator-driven remote optimization strategy improve guideline-directed medical therapy in patients with HFrEF?
Population
Patients with HF and EF <= 40% receiving longitudinal follow-up at Brigham and Women's Hospital
Comparison
Navigator-facilitated remote GDMT titration vs not reported
Design
Study rationale and design of a remote GDMT optimization program
Authors
Loading...
May support remote GDMT optimization in HFrEF; leaves open need for randomized confirmation before practice change.
Does a navigator-driven remote optimization strategy improve guideline-directed medical therapy in patients with HFrEF?
A navigator-led remote management strategy may represent a scalable population-level approach to optimize GDMT in patients with HFrEF.
Blood et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: